Director at 20/20 Biolabs (AIDX) converts Series A-2 preferred into common

Rhea-AI Filing Summary

20/20 Biolabs, Inc. director Richard M. Cohen acquired 7,700 shares of common stock through the conversion of preferred stock. On February 19, 2026, all 7,700 shares of Series A-2 preferred stock he held automatically converted into an equivalent number of common shares when the company’s common stock listed on the Nasdaq Capital Market. Following the transaction, he directly held 7,700 common shares and no Series A-2 preferred shares. This was a non-cash derivative conversion, not an open-market purchase.

Insider Trade Summary

7,700 shares exercised/converted

Mixed 2 txns

Insider COHEN RICHARD M

Role Director

Type	Security	Shares	Price	Value
Conversion	Series A-2 Preferred Stock	7,700	$0.00	--
Conversion	Common Stock	7,700	$0.00	--

Holdings After Transaction: Series A-2 Preferred Stock — 0 shares (Direct); Common Stock — 7,700 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

COHEN RICHARD M

(Last) (First) (Middle)

C/O 20/20 BIOLABS, INC.

15810 GAITHER ROAD, SUITE 235

(Street)

GAITHERSBURG MD 20877

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
20/20 Biolabs, Inc. [ AIDX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		C(1)		7,700	A	$0	7,700	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A-2 Preferred Stock(1)	(1)	02/19/2026		C(1)			7,700	(1)	(1)	Common Stock	7,700	(1)	0	D

Explanation of Responses:

1. On February 19, 2026, all shares of series A-2 preferred stock held by the Reporting Person were automatically converted into an equivalent number of shares of common stock upon the listing of the Issuer's common stock on the Nasdaq Capital Market. The series A-2 preferred stock had no expiration date.

	/s/ Richard M. Cohen	02/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did 20/20 Biolabs (AIDX) report for Richard M. Cohen?

20/20 Biolabs reported that director Richard M. Cohen acquired 7,700 common shares via conversion of Series A-2 preferred stock. The preferred shares automatically converted into an equivalent number of common shares when the company’s common stock listed on the Nasdaq Capital Market on February 19, 2026.

How many 20/20 Biolabs (AIDX) shares did Richard M. Cohen own after the reported Form 4?

After the transaction, Richard M. Cohen directly owned 7,700 shares of 20/20 Biolabs common stock. All 7,700 Series A-2 preferred shares he previously held were converted, leaving him with no remaining preferred shares and the same number of common shares instead.

Was Richard M. Cohen’s 20/20 Biolabs (AIDX) transaction a market purchase or sale?

The transaction was not a market purchase or sale. It was an automatic conversion of 7,700 Series A-2 preferred shares into 7,700 common shares, triggered by the listing of 20/20 Biolabs’ common stock on the Nasdaq Capital Market on February 19, 2026.

What triggered the conversion of Series A-2 preferred stock for 20/20 Biolabs (AIDX)?

The conversion was triggered when 20/20 Biolabs’ common stock listed on the Nasdaq Capital Market on February 19, 2026. At that time, all Series A-2 preferred shares held by Richard M. Cohen automatically converted into an equivalent number of common shares under their terms.

Did the 20/20 Biolabs (AIDX) Series A-2 preferred stock have an expiration date?

The Series A-2 preferred stock had no expiration date. Instead of expiring, all Series A-2 preferred shares held by Richard M. Cohen automatically converted into common stock when 20/20 Biolabs’ common shares were listed on the Nasdaq Capital Market on February 19, 2026.